Praetego, Inc.
Praetego is a company involved in life science innovations, as highlighted in an interview on Life Science Nation. The company focuses on advancing life science research and development.
Industries
Nr. of Employees
small (1-50)
Praetego, Inc.
Durham, North Carolina, United States, North America
Products
PTG-630
PTG-630 is a drug candidate in preclinical development aimed at slowing or preventing the progression of Alzheimer’s disease and treating Diabetic Peripheral Neuropathy.
PTG-670
PTG-670 is an Amadorin under development for Alzheimer’s Disease and Dementia, focusing on neuroprotection.
Amadorins
Amadorins are Praetego’s proprietary small molecules designed to inhibit the oxidative breakdown of proteins and lipids modified by glucose, targeting AGE-related diseases.
Diabetic Retinopathy treatment
An oral treatment candidate for Diabetic Retinopathy, aiming to preserve visual function by initiating treatment before significant retinal damage.
PTG-630
PTG-630 is a drug candidate in preclinical development aimed at slowing or preventing the progression of Alzheimer’s disease and treating Diabetic Peripheral Neuropathy.
PTG-670
PTG-670 is an Amadorin under development for Alzheimer’s Disease and Dementia, focusing on neuroprotection.
Amadorins
Amadorins are Praetego’s proprietary small molecules designed to inhibit the oxidative breakdown of proteins and lipids modified by glucose, targeting AGE-related diseases.
Diabetic Retinopathy treatment
An oral treatment candidate for Diabetic Retinopathy, aiming to preserve visual function by initiating treatment before significant retinal damage.